Study guide
8.1 Breast-Conserving Surgery, Margin Standards & Mastectomy Techniques
CBCN Certified Breast Care Nurse Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction: The CBCN Exam
CBCN Exam Facts, 2026 Blueprint & Study Plan
2 Chapter 1: Breast Health, Examination & Benign Conditions (Care Continuum)
1.1 Breast Anatomy, Vascular Supply & Hormonal Physiology 1.2 Clinical Breast Examination & Breast Awareness Education 1.3 Benign Breast Conditions, Mastalgia & Fibrocystic Changes
3 Chapter 2: Screening, Breast Density & Special Populations (Care Continuum)
2.1 Screening Modalities, Breast Density & Pharmacologic Risk Reduction 2.2 Screening & Breast Health in Special Populations
4 Chapter 3: Cancer Risk Assessment & Genetics (Care Continuum)
3.1 Proliferative Lesions, Atypia & High-Risk Benign Pathology 3.2 Breast Cancer Risk Models (Gail, Tyrer-Cuzick, Claus, BRCAPRO) 3.3 Hereditary Cancer Syndromes & Genetic Evaluation
5 Chapter 4: Patient Navigation, Surveillance & Survivorship (Care Continuum)
4.1 Patient Navigation, Barriers to Care, Social Determinants & Interprofessional Collaboration 4.2 Survivorship Care Planning, Surveillance Intervals & Recurrence Monitoring 4.3 Secondary Prevention, Physical Activity, Nutrition & Wellness Guidance
6 Chapter 5: Carcinogenesis & Diagnostic Evaluation (Diagnosis and Staging)
5.1 Carcinogenesis: How Breast Cancer Develops and Spreads 5.2 Clinical Assessment, Diagnostic Imaging & BI-RADS Categorization 5.3 Breast Biopsy Modalities & Image-Guided Localization Techniques
7 Chapter 6: Pathology, Biomarkers & Genomic Testing (Diagnosis and Staging)
6.1 Histopathology: In Situ Carcinomas & Invasive Carcinoma Subtypes 6.2 Receptor Biomarkers (ER, PR, HER2, Ki-67) & Molecular Subtypes 6.3 Multigene Genomic Assays & Recurrence Risk Stratification
8 Chapter 7: Clinical & Pathologic Staging (Diagnosis and Staging)
7.1 AJCC TNM Staging System (Anatomic vs Prognostic Staging) 7.2 Staging Workup: When to Use MRI, CT, Bone Scan & PET
9 Chapter 8: Breast Surgery, Axillary Staging & Reconstruction (Treatment Modalities)
8.1 Breast-Conserving Surgery, Margin Standards & Mastectomy Techniques 8.2 Axillary Staging: Sentinel Lymph Node Biopsy vs. Axillary Dissection 8.3 Post-Mastectomy Reconstruction & Oncoplastic Surgery
10 Chapter 9: Radiation Therapy & Chemotherapy (Treatment Modalities)
9.1 Radiation Therapy: Whole Breast, Chest Wall, Regional Nodal & Partial Breast Irradiation 9.2 Neoadjuvant vs. Adjuvant Chemotherapy Principles & Standard Regimens
11 Chapter 10: Endocrine, HER2-Targeted & Novel Systemic Therapies (Treatment Modalities)
10.1 Endocrine Therapy: SERMs, Aromatase Inhibitors, Ovarian Suppression & SERDs 10.2 HER2-Targeted Monoclonal Antibodies, Antibody-Drug Conjugates & Kinase Inhibitors 10.3 CDK4/6 Inhibitors, PARP Inhibitors & Immune Checkpoint Blockade 10.4 Trop-2 Antibody-Drug Conjugates, PI3K/AKT/mTOR Inhibitors & New Oral SERDs
12 Chapter 11: Specific Conditions & Special Populations (Treatment Modalities)
11.1 Triple-Negative Breast Cancer: Treatment Considerations 11.2 HER2-Positive Breast Cancer: Treatment Considerations 11.3 Inflammatory Breast Cancer & Paget Disease of the Nipple 11.4 Phyllodes Tumors & Breast Angiosarcoma 11.5 Treatment Considerations for Special Populations
13 Chapter 12: Symptom Management & Supportive Care (Nursing Practice)
12.1 Acute Chemotherapy Toxicities, Supportive Regimens & Oncologic Emergencies 12.2 Lymphedema Pathophysiology, ISL Staging & Complete Decongestive Therapy (CDT) 12.3 Musculoskeletal Toxicities, Bone Health & Vasomotor/GSM Relief 12.4 Complementary & Integrative Modalities 12.5 Cancer Rehabilitation: Physical, Occupational & Pelvic Floor Therapy
14 Chapter 13: Oncologic Emergencies (Nursing Practice)
13.1 Oncologic Emergencies I: Spinal Cord Compression, Hypercalcemia, Tamponade & SVC Syndrome 13.2 Oncologic Emergencies II: Hypersensitivity & Anaphylaxis, Sepsis, Pleural Effusion & Thromboembolism
15 Chapter 14: Professional Practice, Clinical Trials & Self-Care (Nursing Practice)
14.1 Professional Practice: Guidelines, Ethics, Legislation, Outreach & Accreditation 14.2 Clinical Trials in Breast Oncology 14.3 Nurse Self-Care: Compassion Fatigue, Burnout, Moral Distress & Substance Use
16 Chapter 15: Psychosocial Dimensions of Care (Psychosocial Dimensions)
15.1 Psychosocial Distress, Coping, Grief & Palliative Care 15.2 Culture, Spirituality, Sexual & Gender Identity, Age & Healthcare Disparities 15.3 Family & Caregiver Dynamics 15.4 Altered Body Image 15.5 Reproductive & Sexual Health
8.1 Breast-Conserving Surgery, Margin Standards & Mastectomy Techniques
Key Takeaways Explain This Topic AI
Breast-conserving surgery (BCS) combined with adjuvant radiation therapy provides equivalent overall survival compared to total mastectomy for early-stage breast cancer, but is ruled out by diffuse malignant-appearing microcalcifications, disease that cannot be cleared with acceptable cosmesis, diffusely positive margins, or radiation that would fall during pregnancy; prior chest radiation and active connective tissue disease are relative contraindications.
The SSO/ASTRO surgical consensus guideline establishes 'no ink on tumor' as the definitive negative margin standard for invasive breast cancer treated with whole-breast irradiation; routine re-excision for close but negative margins does not improve locoregional control.
For pure ductal carcinoma in situ (DCIS), the consensus negative surgical margin is a minimum of 2 mm; margins under 2 mm are associated with higher rates of ipsilateral recurrence and warrant re-excision unless contraindicated by anatomy.
Nipple-sparing mastectomy (NSM) preserves the complete skin envelope and nipple-areolar complex but requires a primary tumor distance greater than 2 cm from the nipple, a negative retroareolar margin, and absence of skin or nipple involvement.
Postoperative management of closed-suction Jackson-Pratt (JP) drains requires daily output tracking and milking of tubing; drains are removed when output is less than 30 mL per 24 hours for 1 to 2 consecutive days, while ipsilateral shoulder abduction is restricted to 90 degrees or less until drain removal.
Last updated: September 2026
Principles of Breast-Conserving Surgery (BCS)
Breast-conserving surgery (BCS)—variously termed lumpectomy, wide local excision, or partial mastectomy—aims to resect the primary breast malignancy with an adequate rim of normal surrounding parenchyma while preserving the natural cosmetic contour of the breast. Landmark randomized clinical trials with long-term follow-up exceeding 20 years, including the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-06 trial and the Milan I trial directed by Umberto Veronesi, definitively established that BCS followed by whole-breast radiation therapy (WBRT) yields equivalent overall survival (OS) and disease-free survival (DFS) compared to total mastectomy for stage I and stage II invasive breast carcinomas.
Absolute Contraindications to Breast-Conserving Surgery
Patient selection for BCS requires rigorous multidisciplinary evaluation. When specific clinical, radiologic, or pathological barriers prevent either complete oncologic clearance or safe delivery of adjuvant radiotherapy, mastectomy remains mandatory. Using the NCCN framework, absolute contraindications include:
Widespread Disease That Cannot Be Excised With Negative Margins and Acceptable Cosmesis : Extensive or multicentric disease that local excision cannot clear with a satisfactory cosmetic result. Clinical distinction : Multicentric disease involves separate quadrants, whereas multifocal disease refers to multiple tumors within one quadrant. Multicentricity alone is no longer an automatic contraindication: the ACOSOG Z11102 (Alliance) trial reported a 5-year local recurrence rate of about 3% when women with two or three ipsilateral foci had lumpectomy with negative margins plus whole-breast radiation, so breast conservation can be offered to selected patients with two or three foci.
Diffuse, Widespread Malignant-Appearing Microcalcifications : Extensive, branching, pleomorphic, or indeterminate calcifications scattered across multiple quadrants on mammography that preclude achieving complete microscopic clearance without total mastectomy.
Diffusely Positive Pathologic Margins : Positive margins that persist after reasonable re-excision attempts, so clearance is impossible without mastectomy.
Radiation That Would Have to Be Given During Pregnancy : Radiation therapy is contraindicated during gestation because of fetal risk. Breast-conserving surgery is still possible during pregnancy (especially in the second and third trimesters) when radiation can be deferred until after delivery, often because chemotherapy is given in between; a first-trimester diagnosis more often leads to mastectomy.
Biallelic (Homozygous) ATM Mutation : Patients with ataxia-telangiectasia are extremely radiosensitive, so radiation-based breast conservation is avoided.
Relative Contraindications to Breast-Conserving Surgery
Relative contraindications warrant individualized multidisciplinary risk stratification:
Active Connective Tissue / Collagen Vascular Diseases : Active systemic lupus erythematosus (SLE) and systemic sclerosis (scleroderma) are associated with severe microvascular hypersensitivity to therapeutic radiation, resulting in extensive cutaneous ulceration, ischemic chest wall necrosis, and intractable myositis. Rheumatoid arthritis and Hashimoto thyroiditis are not absolute contraindications.
Unfavorable Tumor-to-Breast Size Ratio : A large primary tumor (e.g. 4 to 5 cm) situated within a small, compact breast. Although technically resectable, standard lumpectomy would result in severe parenchymal volume loss and unacceptable cosmetic asymmetry unless volume replacement oncoplastic surgery or neoadjuvant systemic therapy is employed to downstage the primary tumor prior to surgical resection.
Deleterious Germline Pathogenic Variants ( BRCA1 , BRCA2 , TP53 ) : Patients harboring high-penetrance genetic mutations have identical locoregional control of the index lesion with BCS plus radiation compared to non-carriers. However, their extraordinarily high lifetime risk of secondary ipsilateral breast events (1-2% per year) and contralateral breast cancer (30-50% cumulative lifetime risk) frequently leads to the clinical selection of bilateral risk-reducing mastectomy.
Prior Radiation to the Breast or Chest Wall : Mantle radiation for Hodgkin lymphoma or prior breast radiotherapy was once treated as an absolute barrier; NCCN now lists it as relative because repeat partial-breast irradiation can be considered when prior doses and volumes are known. Cumulative soft-tissue tolerance, fibrosis, and rib injury remain the concerns.
Tumor Larger Than 5 cm or Focally Positive Margins : Handled case by case, often with neoadjuvant therapy or oncoplastic techniques.